n-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
type 2 diabetes mellitus 1 endocrinologydiseases
diabetes mellitus 1 endocrinologydiseases
metabolic syndrome 6 endocrinologydiseases
obesity 2 endocrinologydiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
diabetes mellitus 2364 glucose tolerance [[1]]. Considering that patients with MetS have shown to be a predictor of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) [[2],[3],[4]], it is important and necessary to curb the incidence
metabolic syndrome 624 date (collection): 7/2017AbstractThe associations between n-3 polyunsaturated fatty acids (PUFAs) and metabolic syndrome (MetS) risk have demonstrated inconsistent results. The present study aimed to investigate whether higher
metabolic syndrome 5002 acid (EPA), docosapentaenoic acid (DPA), docosahexaenoic acid (DHA), omega-3, and n-3 were paired with metabolic syndrome as search terms. Using Google and Baidu Scholar, manual searches were also scrutinized from recent meta-analyses,
metabolic syndrome 21664 selection process.Figure 2Forest plot to quantify the association of circulating n-3 PUFAs or EPA with metabolic syndrome risk. The pooled ORs were calculated by using a random-effects model for the highest versus lowest category.
metabolic syndrome 22044 acid; OR, odd ratio.Figure 3Forest plot to quantify the association of circulating DPA or DHA with metabolic syndrome risk. The pooled ORs were calculated by using a random-effects model for the highest versus lowest category.
metabolic syndrome 23015 docosahexaenoic acid; DPA, docosapentaenoic acid.Figure 6The underlying mechanisms of n-3 PUFAs protecting metabolic syndrome . Dysfunctions of lipid metabolism and inflammation contribute to metabolic syndrome. The high lipolytic
metabolic syndrome 23099 PUFAs protecting metabolic syndrome. Dysfunctions of lipid metabolism and inflammation contribute to metabolic syndrome . The high lipolytic rate in visceral adipose provides the liver with large amounts of FFAs. Impaired
obesity 2125 combination of three or more different components of cardiometabolic risk factors, including central obesity , hypertension, dyslipidemia (elevated triglyceride (TG) and low high-density lipoprotein cholesterol
obesity 19981 inflammation contributes to the initiation, propagation and development of metabolic disorders, including obesity , insulin resistance, T2DM and CVD [[52],[53]]. Accumulating evidence has suggested that n-3 PUFAs and
type 2 diabetes mellitus 2357 impaired glucose tolerance [[1]]. Considering that patients with MetS have shown to be a predictor of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD) [[2],[3],[4]], it is important and necessary to curb the incidence

You must be authorized to submit a review.